Milan Cabrnoch works in the European Parliament on pharmaceutical market modernization

It is almost unbelievable that a directive which pharmaceutical market follows nowadays was issued in the year 1989. This directive has not been changed since the time it came in force and it reflects conditions on the pharmaceutical market which existed more than 20 years ago.

Milan Cabrnoch considers this fact as a mistake. "These conditions have principally changed not only due to arrival of generic drugs on market which represent less costing alternatives but as well as due to development of modern (and more expensive) pharmaceutics" says Milan Cabrnoch.

Market development is very dynamic but it is being hindered by our current out of date directive. Legislative process related to launching new pharmaceutics on the market is usually lengthy which leads to availability postponement of pharmaceutics for citizens. In the Czech Republic it is the State Institute for Drug Control which is in charge of this field but the situation is not an exception either.
It is Milan Cabrnoch who is a shadow reporter for these amendments which reduce the amount of time spent on pricing and deciding about reimbursement by the health insurance. Nevertheless it does not intervene pricing and reimbursement in Member States.

Milan Cabrnoch comments on unnecessary long terms: "New pharmaceutics should be available for patients in time. Authorities must work quickly and effectively on behalf of patients and not for a comfort of clerks." He hopes that he will manage to convince also his colleagues for these changes.
On today’s voting the European Parliament decided to enlarge the terms proposed by the Commission and delivered a proposal for changes to the Commission.